Prescribing information

 

Welcome to the Ophthalmology podcasts, developed by Novartis Pharmaceuticals UK Ltd with a number of leading healthcare professionals from the UK to provide relevant insights for the medical retina community.

The podcast series is available to listen to below.

Click here for ▼Beovu® (brolucizumab) prescribing information

 

Series 1 – the impact of COVID-19 on medical retina service

 

 Image of Mandeep Bindra within a circle outlined in Novartis blue

Mandeep Bindra
Stoke Mandeville

 Image of Louise Downey within a circle outlined in Novartis blue

Louise Downey
Hull University Teaching Hospitals

 Image of Patrick Richardson within a circle outlined in Novartis blue

Patrick Richardson
Royal Derby Hospital

 

 

Join Dr Mandeep Bindra, Dr Louise Downey and Dr Patrick Richardson, at your leisure, as they reveal their valuable learnings. We have 5 podcast episodes available.

Series 1, E1 – Impact of COVID-19 on medical retinal service

 

 Image of Mandeep Bindra within a circle outlined in Novartis blue

Mandeep Bindra

 

 

 

In the first episode, Dr Mandeep Bindra evaluates the disruptive effect the COVID-19 pandemic has had on the medical retina service.

Series 1, E2 – Virtual clinics: how to maximise their impact

 

 Image of Louise Downey within a circle outlined in Novartis blue

Louise Downey

 

 

In the second episode, Dr Louise Downey explains the impact COVID-19 has had on her service; she also highlights the importance of virtual clinics, explains patients’ reactions to these virtually-led consultations and shares learnings on how to set up virtual clinics.

Series 1, E3 – Communicating with patients in times of crisis

 

 Image of Mandeep Bindra within a circle outlined in Novartis blue

Mandeep Bindra

 

 

In this episode, Dr Mandeep Bindra focuses on how communication with patients has changed since the COVID-19 pandemic, the different anxieties experienced by patients and how best to communicate given the circumstances.

Series 1, E4 – From audit to service implementation

 

 Image of Patrick Richardson within a circle outlined in Novartis blue

Patrick Richardson

 

 

In this episode, Dr Patrick Richardson shares learnings from running an audit and how the results were implemented in a service design change. The 3-year audit, which was carried out between May 2013 and May 2016, documented the outcomes of patients receiving anti-VEGF injections for the treatment of visual impairment due to DMO. The data from the audit was presented during the Nottingham Eye Symposium in January 2020 and was also discussed by Dr Richardson during a Novartis webinar, which you can watch here on-demand >.

Series 1, E5 – The impact of COVID-19 on DMO patients

 

 Image of Mandeep Bindra within a circle outlined in Novartis blue

Mandeep Bindra

 

 

In this episode, Dr Mandeep Bindra discusses the psychological and physical impact of COVID-19 on DMO patients, and the role of an ophthalmologist dealing with those patients. The podcast focuses on the future of patient assessment, discussing which information is needed and how best to support the patient with their diabetes, as well as DMO.

Series 1, E6 – Panel discussion: The future of patient assessment

 

 Image of Mandeep Bindra within a circle outlined in Novartis blue

Mandeep Bindra

 Image of Louise Downey within a circle outlined in Novartis blue

Louise Downey

 

 

In this podcast, Drs Mandeep Bindra and Louise Downey deal with pertinent questions on how the addition of virtual patient assessments to the normal face-to-face assessments have worked in practice across medical retina teams. In particular, the experts discuss the relevance of monitoring, and how well the changes to local protocols since the pandemic have worked, as well as the main learnings that can be taken forward to educate local retina teams when managing patients with DMO.

Indications1

LUCENTIS 0.5 mg is indicated in adults for:

  • The treatment of neovascular (wet) age-related macular degeneration (AMD)
  • The treatment of visual impairment due to diabetic macular oedema (DMO)
  • The treatment of proliferative diabetic retinopathy (PDR)
  • The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
  • The treatment of visual impairment due to choroidal neovascularisation (CNV).

LUCENTIS 0.2 mg is indicated in preterm infants for:

The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

DMO, diabetic macular oedema.

References

  1. LUCENTIS® (ranibizumab) Summary of Product Characteristics, July 2020. 
Rate this content: 
Average: 3.3 (4 votes)
UK | May 2021 | 127256
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]